Group 1 - The core viewpoint of the article highlights the sales situation of the new aluminum magnesium carbonate suspension product launched by Minsheng Health, which is currently in the招商 (recruitment) and铺货 (distribution) phase [1] - The product is primarily sold through offline pharmacy terminals, indicating a focus on traditional retail channels for its distribution [1] - Current orders for the product are stable; however, there are delivery pressures due to external production factors, including the Spring Festival holiday and production scheduling [1] Group 2 - The company expects that the delivery situation will improve soon, suggesting confidence in resolving the current production challenges [1]

证券代码： 301507 证券简称：民生健康 杭州民生健康药业股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | □ 特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 □ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 （券商策略会） ☑ | | 参与单位名称及 | 方正证券 王泽华、谌保罗 | | 人员姓名 | 华夏基金 李柄桦 | | | 华夏久盈资产管理有限责任公司 于海申 | | | 东兴证券 高怡宁 | | | 天治基金 王策源 | | | 上海混沌投资（集团）有限公司 黎晓楠 | | | 荷荷北京 唐巍、陈亮 | | 时间 | 2025 年 2 月 19 日 (周三) 上午 10:00-11:00 | | 地点 | 线上/电话会议 | | 上市公司接待人 | 陈稳竹 董事会秘书 | | 员姓名 | 证券事务代表 鲍蔚霞 | | | 证券事务助理 潘亦乐 | | | 一、公司介绍环节 | | | 由证券事务代表通过公司发展历史、主要业务板块及产品等 | | | 几部分内容，向投资 ...

酒石酸伐尼克兰片用于成人戒烟。伐尼克兰是烟碱型乙酰胆碱受体 α4β2 亚 型的选择性部分激动剂，对神经中该受体具有高度亲和力。伐尼克兰与 α4β2 受 证券代码：301507 证券简称：民生健康 公告编号：2025-001 杭州民生健康药业股份有限公司 关于公司取得酒石酸伐尼克兰片药品批文的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，杭州民生健康药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的酒石酸伐尼克兰片《药品补充申请批准通知书》，现将相 关情况公告如下： 一、药品的基本情况 药品名称：酒石酸伐尼克兰片 英文名/拉丁名：Varenicline Tartrate Tablets 通知书编号：2025B00553 主要成份：酒石酸伐尼克兰 剂型：片剂 规格：0.5mg（按 C13H13N3 计） 注册分类：化学药品 药品有效期：36 个月 药品批准文号：国药准字 H20233137 上市许可持有人：名称：杭州民生健康药业股份有限公司 地址：浙江省杭州市临平区东湖街道新天路 101 号 二、药品相关情况 杭州民生健康药 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-060 杭州民生健康药业股份有限公司 关于与中科嘉亿等主体签署《战略合作协议》的 公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、杭州民生健康药业股份有限公司（以下简称"民生健康"或"公司"）拟通 过全资子公司民生中科嘉亿（浙江）生物工程有限公司（以下简称"民生中科（浙 江）"）收购民生中科嘉亿（山东）生物工程有限公司（以下简称"标的公司"） 现有股东持有的标的公司100%股权。即标的公司现有股东以其所持标的公司全部股 权增资民生中科（浙江），增资完成后，民生中科（浙江）注册资本增加至16,000万 元人民币，标的公司现有股东将合计持有民生中科（浙江）45%的股权。民生健康 拟放弃本次民生中科（浙江）增资扩股的优先认购权，放弃权利涉及的注册资本金 额为7,200万元人民币。 2、本次交易完成后，公司持有民生中科（浙江）的股权将由100%被稀释至55%， 民生中科（浙江）由公司全资子公司变更为控股子公司。标的公司成为民生中科（浙 江）的全资子公司并纳入公司的合并报表范围。 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-059 杭州民生健康药业股份有限公司（以下简称"公司"）第二届董事会第六次 会议于2024年12月23日以现场及通讯方式召开，本次会议通知于2024年12月20日 以书面、通讯等方式发出。本次会议由竺福江先生召集并主持，应到董事9人， 实到董事9人，全体监事、高级管理人员列席会议。本次会议的召集、召开符合 《中华人民共和国公司法》（以下简称"《公司法》"）、《杭州民生健康药业股份有 限公司章程》（以下简称"《公司章程》"）以及有关法律、法规的有关规定，所作 决议合法有效。 杭州民生健康药业股份有限公司 二、董事会会议审议情况 （一）审议通过了《关于与中科嘉亿等主体签署<战略合作协议>的议案》 经审议，董事会认为：本合作协议的签署，将有利于拓展公司在益生菌领域 的业务发展空间，提升研发实力和市场竞争力，增强公司综合影响力，有助于进 一步提升公司的业务规模和盈利能力，符合公司长期发展战略、业务布局和全体 股东的利益。因此，董事会同意公司与中科嘉亿（山东）投资控股有限公司（简 称"中科嘉亿"）等主体签署《战略合作协议》，同意公司通过全资子公司民生中 科 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-058 杭州民生健康药业股份有限公司 关于公司及全资子公司取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、取得发明专利的基本情况 专利权人：杭州民生健康药业股份有限公司 浙江民生健康科技有限公司 授权公告日：2024 年 12 月 20 日 专利权期限：二十年，自申请日起算 本发明专利涉及质控检测技术领域，具体涉及一种从维生素矿物质复合制剂 中提取维生素 K2 的提取液及提取方法。本专利技术能有效溶解维生素 K2 微囊 壁材，对维生素 K2 提取效果优异，能有效提高从维生素矿物质复合制剂中维生 素 K2 的质控检测准确度。本发明专利涉及的技术已经应用于公司现有产品的检 近日，杭州民生健康药业股份有限公司（以下简称"公司"）及公司全资子 公司民生中科嘉亿（浙江）生物工程有限公司（原浙江民生健康科技有限公司） 收到国家知识产权局颁发的一项发明专利证书，具体情况如下： 发明名称：一种从多种维生素矿物质复合制剂中提取维生素 K2 的提取液及 提取方法 证书号：第 7614 ...

Group 1: Company Overview - The company was established in 2009, spun off from the controlling shareholder, Minsheng Pharmaceutical, and formed a joint venture with Sanofi in 2010, which was fully acquired in 2017 [1] - The company focuses on dietary supplements, with the per capita consumption of such products in China being approximately 1/5 of that in developed countries [2] Group 2: Product Performance - The sales of the multi-dimensional element tablets (21) are expected to show steady growth, indicating a strong market potential [2] - The main growth driver in the health product category is the Vitamin and Mineral series, particularly the "21 Jinweita Peach Blossom Vase" targeted at adult women [2] Group 3: Market Strategy - The company is expanding its sales channels through the "21 Jinweita" brand, which includes online distribution and partnerships, impacting overall gross margins [2] - The company is focusing on building a comprehensive ecosystem in the probiotic sector through strategic partnerships [3] Group 4: Future Directions - Future product development will include probiotics, traditional health products, OTC drugs, and online distribution, aiming to enhance business scale and profitability [3] - The company is open to mergers and acquisitions in the health sector, aligning with its strategic development plans [3]

Summary of the Conference Call for Hangzhou Minsheng Health Pharmaceutical Co., Ltd. Company Overview - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. focuses on the health sector, specializing in the research, production, and sales of vitamins, minerals, and other over-the-counter health food products [1] Financial Performance - For the fiscal year 2024, the company reported a revenue of 641 million yuan, representing a year-on-year increase of 10.23% [1] - The net profit attributable to shareholders was 91.83 million yuan, reflecting a growth of 7.24% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 87.21 million yuan, which is a 10.13% increase year-on-year [1] Strategic Initiatives - The company aims to enhance product innovation and research by focusing on new products, new business models, and new projects as part of its core strategy for 2024 [2] - There is an emphasis on expanding the product matrix in the OTC health food sector, particularly in micro-mineral and other categories [2] Business Development - The company achieved a 15.7% increase in net profit for the first quarter of 2024, amounting to 6.3 million yuan, with a 6.5% growth compared to the same period last year [3] - The launch of the carbonic enzyme mixed solution in the OTC sector is highlighted as a significant achievement [3] - Strategic partnerships in the medical field are being pursued to accelerate growth and enhance resource integration [3] - New health brands, such as Minsheng Tongchun Medical Aesthetics, are being introduced alongside existing product lines [3] Future Outlook - The company plans to continue leveraging its "Four New" strategy to deepen its focus on micro-mineral therapeutic OTC medications and accelerate the launch of new products [4] - There is a commitment to continuously improve the product pipeline to support rapid growth in performance [4] - The management expresses a desire for feedback from investors and stakeholders to further enhance company operations [4]

Financial Performance - The company's revenue for Q3 2024 was CNY 122,412,416.08, representing a 3.65% increase year-over-year, while the year-to-date revenue reached CNY 519,847,972.13, up 6.98% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was CNY 8,909,041.54, a decrease of 23.33% year-over-year, with year-to-date net profit at CNY 86,178,415.70, an increase of 5.52%[3]. - The basic earnings per share for Q3 2024 was CNY 0.02, down 50.00% year-over-year, while the diluted earnings per share also stood at CNY 0.02, reflecting the same decline[3]. - The net profit for Q3 2024 was CNY 86,178,415.70, an increase of 5.5% compared to CNY 81,672,290.77 in Q3 2023[23]. - Operating profit for Q3 2024 reached CNY 100,821,117.14, up from CNY 93,443,439.27 in the same period last year, reflecting a growth of 7.4%[23]. - The total comprehensive income for Q3 2024 was CNY 86,178,415.70, compared to CNY 81,672,290.77 in Q3 2023, indicating a growth of 5.5%[23]. Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to CNY 1,708,017,882.54, a 3.65% increase from the end of the previous year[3]. - The total equity attributable to shareholders increased to ¥1,523,583,194.28 from ¥1,473,060,211.58, reflecting a growth of approximately 3.4%[21]. - The company's cash and cash equivalents decreased to ¥389,824,520.26 from ¥428,301,750.63, a decline of approximately 9.5%[20]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was CNY 101,039,367.62, showing a 20.81% increase compared to the same period last year[3]. - Cash flow from operating activities increased to CNY 101,039,367.62, compared to CNY 83,634,005.05 in Q3 2023, marking a growth of 20.8%[24]. - The company experienced an increase in cash inflows from operating activities, totaling CNY 603,654,399.05, compared to CNY 492,013,037.77 in the previous year[24]. - The net cash flow from investing activities was negative at CNY -102,836,717.85, primarily due to cash used for purchasing financial products[8]. - The company reported a net cash outflow from investing activities of CNY -102,836,717.85, compared to CNY -72,777,857.74 in Q3 2023[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,480, with the largest shareholder holding 66.75% of the shares[9]. - The company reported a total of 238,000,000 restricted shares at the beginning of the period, with no shares released during the period, maintaining the same number at the end[13]. - Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd. holds 10,423,629 unrestricted shares, representing the largest shareholder[11]. - The top 10 unrestricted shareholders collectively hold 272,008,733 shares, with a significant portion held by Zhejiang Puhua Tianqin and Hangzhou Shobo Equity Investment[14]. - The total number of unrestricted shares held by the top 10 shareholders is 272,008,733, with Zhejiang Puhua Tianqin being the largest[11]. Strategic Initiatives - The company signed a strategic cooperation intention agreement in the probiotics field, aiming for resource sharing and enhancing market competitiveness[15]. - The strategic cooperation agreement is expected to enhance the company's business scale and profitability, although its impact on 2024 performance remains uncertain[15]. - The company’s market expansion strategy includes collaboration with partners in the probiotics sector, which aligns with its long-term development goals[15]. - The company approved a restricted stock incentive plan, granting 3,320,000 shares at a price of 6.67 CNY per share to 40 eligible participants[16]. - The company’s stock incentive plan was approved in September 2024, indicating a focus on employee motivation and retention[16]. Operational Metrics - Operating costs amounted to ¥429,009,479.08, up from ¥397,746,837.53, reflecting a rise in operating expenses[22]. - Research and development expenses were ¥21,522,017.88, slightly down from ¥22,898,659.93 in the previous period[22]. - Accounts receivable increased by 35.81% to CNY 46,458,110.58 due to higher revenue from core business operations[6]. - Accounts receivable rose to ¥46,458,110.58 from ¥34,207,790.42, showing a significant increase of 36%[20]. - Inventory decreased to ¥86,614,319.58 from ¥105,315,599.46, a reduction of about 17.7%[20].

证券代码：301507 证券简称：民生健康 公告编号：2024-056 杭州民生健康药业股份有限公司 关于开立募集资金现金管理专用 尽管公司选择安全性高、流动性好的投资品种，但金融市场受宏观经济的影 响较大，不排除该等投资受到市场波动的影响。 结算账户的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于2024年4月22日召开 第一届董事会第十六次会议及第一届监事会第十二次会议，并于2024年5月17日 召开2023年年度股东大会，审议通过了《关于使用部分闲置募集资金（含超募资 金）进行现金管理的议案》，同意公司在不影响募集资金投资项目建设和公司正 常经营、不改变募集资金使用用途的前提下，使用最高不超过人民币7.5亿元的暂 时闲置募集资金（含超募资金）进行现金管理，单笔投资产品期限最长不超过12 个月，有效期自公司股东大会审议通过之日起12个月，公司可在上述额度及期限 内滚动使用投资额度。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于使用部分闲置募集资金 ...